Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats ovarian cancer. Sold as Doxorubicin Hydrochloride, Doxil, Oxderys. Every FDA application for this active ingredient: 4 branded and 27 generic. Boxed warning
As of Nov 22, 2026, FDA lists 31 applications for Doxorubicin hydrochloride (sold as Doxorubicin Hydrochloride, Doxil, Oxderys), first approved Aug 7, 1974, with 8 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
AdriacinDrugs with a new dosage indicated for the treatment of breast cancer (preoperative or postoperative chemotherapy in patients with operable breast cancer). · Sandoz Pharma K.K. · Nov 24, 2022
AdriacinDrugs with a revised indication and a new dosage for the relief of symptoms of malignant lymphoma. · Kyowa Hakko Kirin Co., Ltd. · Dec 18, 2014
Doxorubicin HydrochlorideDrugs with a revised indication and a new dosage for the relief of symptoms of malignant lymphoma. · Nippon Kayaku Co., Ltd. · Dec 18, 2014
DoxilA drug with a new indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. · Janssen Pharmaceutical K.K. · Apr 22, 2009
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA